Candidemia is a bloodstream inflection of serious proportions caused by Candida yeast, and is the fourth-most common ...

Bengaluru-based Biocon said that its Q4 profit stood at ₹198.6. The profit was hit by an exceptional item outgo of ₹80.4 ...

Developing a biosimilar requires years of research and significant capital. In-licensing allows companies to acquire or ...

Biocon's transformative journey under Kiran Mazumdar-Shaw highlights a significant succession plan and corporate ...

Biocon’s fair value estimate has been trimmed slightly from ₹420.74 to about ₹416.53, signalling a modest reset in how analysts are sizing up the stock today. That shift lines up with a broader, more ...

Biocon: Nuvama said Q4FY26 growth moderated as Biocon upgraded facilities to scale up capacity in response to anticipated ...

Biocon Executive Chairperson Kiran Mazumdar-Shaw speaks exclusively to Business Today TV in her first interview after ...

The biotech major embarks on a future-focussed vision, with the succession plan in place ensuring seamless leadership ...

Biocon share price rose about 3% despite a 57% drop in Q4 FY26 net profit, as investors focused on revenue growth, margin ...

Biocon Ltd (BOM:532523) reports robust revenue growth driven by biosimilars, strategic debt reduction, and key market expansions despite external challenges.

Succession confirmed: Kiran Mazumdar-Shaw will transition Biocon leadership to her niece Claire over five years, citing her proven leadership in biotech. Pipeline priorities: Biocon plans major ...

Biocon is actively seeking in-licensing opportunities to expand its biosimilars portfolio, focusing on products that ...